IgA Nephropathy Clinical Trials in Beijing, Beijing Municipality
8 recruitingBeijing, Beijing Municipality, China
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 3
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Phase 2
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30 enrolled1 locationNCT07305974
Recruiting
Phase 3
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd.378 enrolled1 locationNCT07014826
Recruiting
TESTING -ON Post-Trial ObservatioNal Cohort Study
Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325
Recruiting
Phase 2
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.80 enrolled2 locationsNCT06670352
Recruiting
Phase 2
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
IgA Nephropathy
Keymed Biosciences Co.Ltd70 enrolled1 locationNCT05775042